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Prostate cancer (PCa) is the most common malignancy detected in males and the second most common
cause of cancer death in western countries. The development of the prostate gland, is ﬁnely regulated by
androgens which modulate also its growth and function. Importantly, androgens exert a major role in
PCa formation and progression and one of the hypothesized mechanism proposed has been linked to the
chromosomal rearrangement of the androgen regulated gene TMPRSS2 with ERG. Androgens have been
therefore used as main target for therapies in the past. However, despite the development of endocrine
therapies (e.g. androgen ablation), when PCa progress, tumors become resistant to this therapeutic
castration and patients develop incurable metastases. A strategy to better understand how patients
respond to therapy, in order to achieve a better patient stratiﬁcation, consists in monitoring the levels of
small noncoding RNAs (microRNAs). microRNAs are a class of small molecules that regulate protein
abundance and their application as biomarkers to monitor disease progression has been intensely
studied in the last years. In this review, we highlight the interactions between microRNAs and endocrine-
related aspects of PCa in tissues. We focus on the modulation of TMPRSS2-ERG and Glucocorticoid Re-
ceptor (GR) by microRNAs and detail the inﬂuence of steroidal hormonal therapies on microRNAs
expression.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer (PCa) is the second leading cause of death from
cancer in males inwestern countries, after lung cancer (Siegel et al.,
2015). The growth of the prostate is regulated by androgens and the
androgen dependency of prostate cancer has been established over
half a century ago (Huggins and Hodges, 1941). Despite the signif-
icant improvement in early cancer detection achieved by PSA
testing and in spite of the development of endocrine therapy
(androgen ablation), when prostate cancer progresses, tumors ac-
quire resistance to this therapeutic castration and are therefore
classiﬁed as castration-resistant prostate cancer (CRPC) (Scher and
Sawyers, 2005).nna-Seiler Haus, Inselspital,
).
Ireland Ltd. This is an open accessThe notion that those prostate cancers arising during androgen
deprivation therapy are androgen independent has been recon-
sidered in the last years (Thompson et al., 2003). Remarkably
indeed, so called “androgen independent” tumors often contain
ampliﬁcation of the gene encoding for the androgen receptor (AR)
(Visakorpi et al., 1995) and in many cases also overexpress the AR
(Linja et al., 2001; Chen et al., 2004) which is sufﬁcient to switch the
growth of PCa cells from androgen dependence to androgen inde-
pendence (Chen et al., 2004). Multiple clinical trials have provided
evidence that CRPCs maintain androgen responsiveness (Tran et al.,
2009; Reid et al., 2010). This effect might be determined by meta-
bolic alterations such as an activation of steroidogenic pathways,
potentially via a de novo intratumoral biosynthesis of steroid hor-
mones, which might facilitate tumor survival in presence of
androgen deprivation therapy (ADT) (Green et al., 2012). In the past
decade, one mechanism of androgens to induce PCa has been hy-
pothesized to be due to chromosomal rearrangement of the
androgen regulated gene TMPRSS2 (transmembrane protease,article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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androgen regulated (Tomlins et al., 2005). This rearrangement
usually occurs during cancer initiation and is also detected as early
event during tumor progression and is present in up to 50e60% of
all prostate tumors (Visakorpi, 2012). In addition to the involve-
ment of androgens and AR, which fundamentally drive PCa, Glu-
cocorticoids (GCs) are another class of steroidal hormones that
recently have been shown to mediate chemotherapy resistance
(Kroon et al., 2016a,b). This opened new possibilities for novel
therapeutic approaches, suggesting the application of GCs and
Glucocorticoid Receptor (GR) antagonism to re-sensitize resistance
to taxane-based drugs in PCa (Kroon et al., 2016a,b).
Endocrine therapy has been used for decades to treat prostate
cancer and its complications. An interesting aspect of the effect that
this therapy can produce, is its inﬂuence on small noncoding RNA
(microRNAs, miRNAs, miRs).
microRNAs are evolutionary conserved short noncoding single-
stranded RNA molecules (approximately 18e22 nucleotides long)
that regulates protein abundance (Ambros, 2004). miRNAs nega-
tively regulate the translation of target mRNA by binding to their 30
untranslated region (UTR) or, although to less extent, to their 50UTR
or coding sequence. In presence of perfect complementarity be-
tween the seed sequence of the miRNA and the mRNA, this will
result in mRNA degradation; alternatively, if the binding is not
perfect, it will produce translational repression (Valinezhad Orang
et al., 2014). microRNAs regulate a vast variety of processes, such as
cell proliferation, motility, apoptosis, maintenance of stem-like
properties and have been implicated in PCa initiation, progression
and metastases.
Each miRNA can modulate the expression of multiple mRNAs
and a single mRNA can be modulated by multiple miRNAs, leading
to a biological complexity which makes miRNAs important regu-
lators of many properties of normal and neoplastic cells. Depending
on the mRNA target genes, miRNAs are classiﬁed in tumor sup-
pressor miRs or onco-miRs and their expression can be aberrant in
cancerous cells. miRNAs represent a relatively recent class of
interesting molecules of potential utility as PCa biomarkers, beside
the employment of proteins andmRNAmeasurement in the clinical
practice. This also opens new possibilities for the use of miRNAs as
predictive markers for endocrine therapy response.
In this review, we focus on the interactions between microRNAs
and endocrine-related aspects of PCa (e.g. androgens and gluco-
corticoids). We speciﬁcally highlight the cross-talk between
microRNAs and the androgen-regulated gene TMPRSS2-ERG and
discuss the effect of endocrine therapy on microRNA expression.
2. microRNA deregulation in prostate cancer
Deregulations of microRNAs, through processes such as pro-
moter methylation, histone modiﬁcations, genomic deletion and
upstream protein alteration (Lujambio et al., 2008; Shi et al., 2008),
have been documented in multiple cancers (Lu et al., 2005; Volinia
et al., 2006). A signiﬁcant portion of microRNAs are indeed local-
ized in the proximity of CpG islands, which are susceptible sites of
epigenetic silencing (Rauhala et al., 2010). A pattern of microRNA
downregulation has indeed been documented for multiple malig-
nancies such as colorectal (Michael et al., 2003; Cummins et al.,
2006) and lung cancer (Yanaihara et al., 2006) and has also been
suggested to reﬂect the lower differentiation stage of the tumor
cells compared with normal cells (Lu et al., 2005; Porkka et al.,
2007). Together, this supports the general pattern of down-
regulation that has been described in prostate cancer in microRNA
expression studies comparing benign vs. cancerous tissues (Porkka
et al., 2007; Ozen et al., 2008; Spahn et al., 2010).
A comprehensive review by Fabris et al., has recentlysummarized the microRNAs that are consistently altered in PCa
tissues in different studies and associated with the same trend of
expression (Fabris et al., 2016). Among the most common micro-
RNAs consistently downregulated in PCa tissues, miR-125b, miR-
145 and Let-7b are associated with altered apoptosis (Porkka et al.,
2007; Ambs et al., 2008; Ozen et al., 2008; Martens-Uzunova et al.,
2012; Larne et al., 2013), miR-205 with cell proliferation (Porkka
et al., 2007; Ambs et al., 2008) and miR-221 and miR-222 with
cell cycle (Porkka et al., 2007; Ambs et al., 2008; Martens-Uzunova
et al., 2012; Larne et al., 2013). On the other hand, among the most
common microRNAs consistently upregulated in PCa tissues, miR-
93 is associated with metastasis and miR-25 with cell prolifera-
tion (Volinia et al., 2006; Martens-Uzunova et al., 2012). Despite the
large volume of information generated with expression analysis of
bulk-tissues, it is becoming increasingly evident that such ap-
proaches also reduce the chances of measuring the contribution of
microRNAs altered in speciﬁc subpopulation of cells (e.g. cancer
progenitor/stem-like cells). Studies focused on microRNA alter-
ations in selectedmetastatic Prostate Cancer Stem Cells (CSCs) have
shown, for example, that a microRNA (miR-25) previously shown to
be increased in PCa “bulk tissues” (Volinia et al., 2006) was
signiﬁcantly downregulated in PCa CSCs and restored expression of
miR-25 resulted in strong reduction of distant growth of PCa cells
inoculated in zebraﬁsh embryos (Zoni et al., 2015a,b).
3. Inﬂuence of endocrine therapy on microRNAs expression
Despite big progresses in the development of new drug delivery
strategies, the applicability of miRNAs as therapeutic agents is still
in its infancy. This is mainly due to multiple challenges such as
speciﬁcity and therapeutic delivery (Conde and Artzi, 2015).
Moreover, the observation of decreased microRNAs during cancer
formation and progression, has led to the concept of microRNA
replacement therapy. An example of this was recently described
with the AR regulating miR-34a (Ostling et al., 2011): it was shown
that nanoparticle-mediated delivery of miR-34a decreased PCa
cells growth in the bone (Gaur et al., 2015). However, microRNAs
may have clear diagnostic and prognostic value and can be
employed as predictors of therapy response and biomarkers
(Junker et al., 2016).
Interestingly, although endocrine therapy has been used for
decades, its inﬂuence on the expression of microRNAs in clinical
tissue specimens has not been extensively analyzed (Lehmusvaara
et al., 2013). In a recent study (Lehmusvaara et al., 2013), the
expression of 723 humanmicroRNAswas analyzed in freshly frozen
specimens from PCa patients treated with goserelin and bicaluta-
mide vs. untreated controls (Lehmusvaara et al., 2012). In this study,
a signiﬁcant difference in microRNAs modulation was registered
upon the treatments. Among the 19 miRNAs with decreased
expression, six were common to both treatments, namely miR-9,
miR-492, miR-210, miR-149, miR-200a and miR-200b (Table 1).
Conversely, among the 23 miRNAs with increased expression, only
three were common to both treatments, namely miR-99a, miR-
125b and miR-100 (Table 1). Strikingly, the majority of the micro-
RNAs measured in this study, displayed a pattern of upregulation
upon treatment. Given that the expression of microRNAs has been
shown to be reduced during PCa progression (Lu et al., 2005;
Martens-Uzunova et al., 2012), this suggests that, the registered
pattern of expression upon treatment, might indicate a therapeutic
response and a reduction of cancerous characteristics
(Lehmusvaara et al., 2013). It is important to note that, the two
treatments investigated in the study, differ signiﬁcantly for the
targeting mechanism: goserelin affects the androgen production
from the testis whereas bicalutamide prevents DHT binding to the
AR. Given the discrepancy in the number of miRs selectively
Table 1
Effect of (endocrine) therapy on microRNA expression.
(endocrine) treatment Downregulated miRNAs Upregulated miRNAs FDA approved References
Trichostatin A (TSA) e miR-9; miR-193 no Rahuala et al., 2010
Mifepristone e miR-99a/100 yes Rane et al., 2016
Goserelin þ Bicalutamide miR-9; miR-492; miR-210; miR-149; miR-200a; miR-200b miR-99a; miR-125b; miR-100 yes Lehmusvaara et al., 2012
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effect of treatments targeting a common pathway seems to be quite
different. Additionally, among themiRs which displayed a decrease,
upon bicalutamide and goserelin treatment, miR-9 was also shown
to be moderately increased upon TSA treatment (discussed in
previous paragraph) (Rauhala et al., 2010). Given that miR-9
directly targets ERG (Nowek et al., 2016), these reinforce the
notion that miR-9 ﬁnely modulates the balance between TMPRSS2-
ERG and AR. Therefore, the decrease of miR-9 upon treatments
targeting AR signaling, suggest that miR-9 might play a role during
therapy resistance in castration resistant phase in PCa. These also
suggest that therapeutic approaches targeting multiple pathways
(e.g. ERG and AR) might be promising to improve patient's
response.
On the other hand, miR-99a and miR-100 displayed an increase
upon bicalutamide and goserelin treatment. Interestingly, inhibi-
tion of the GR by mifepristone (Lin et al., 1995) resulted in an
enhanced miR-99a/100-mediated radiation response in patient-
derived prostate cells (Rane et al., 2016). This support the notion
that, targeting AR and GR pathway simultaneously, might represent
a strategy to prevent resistance to chemotherapy in a later stage of
the disease.
Moreover, in a miRNA library screening to identify anti-
androgen bicalutamide PCa resistance-related microRNAs, miR-
216a was identiﬁed as associated with endocrine resistance
(Miyazaki et al., 2015). Ectopic expression of miR-216a inhibited
bicalutamide-mediated growth suppression of LNCaP cells and
miR-216a was upregulated upon DHT treatment. This suggests that
miR-216a might be employed as marker to monitor endocrine
therapy response in PCa.
Another approach to target endocrine signaling in PCa, is to
interfere with AR coactivators (Culig and Santer, 2013). The tran-
scriptional integrator p300 and its functional homologue CBP, have
been shown to be involved in AR transactivation and to display
acquisition of agonistic properties of hydroxyﬂutamide, a non-
steroidal antiandrogen. Moreover, androgen ablation therapy
resulted in increased expression of p300 and CBP (Debes et al.,
2003; Comuzzi et al., 2004; Heemers et al., 2007). Inhibition of
p300 and CBP by a newly developed molecule C646 (Bowers et al.,
2010) (p300 histone acetyltransferase inhibitor) in androgen-
sensitive and einsensitive cell lines reduced proliferation and in-
vasion (Santer et al., 2011). Recently, we identiﬁed in silico a
signature of 30 validated microRNAs associated with p300/CBP in
the context of EMT in cancer (Zoni et al., 2015a,b). Strikingly,
multiple microRNAs identiﬁed in our signature appear to be rele-
vant for their involvement in endocrine aspects in PCa.
The previously discussed miR-9 was one of the 30 miRs iden-
tiﬁed in our signature and was shown to target p300 (Grimson
et al., 2007). Moreover, in a screening of 1129 miRNAs to identify
microRNAs regulating the AR at protein level, miR-9 was identiﬁed
as direct targets the 30-UTR of AR (Ostling et al., 2011). This reinforce
the identiﬁcation of miR-9 as a promising marker for endocrine
therapy response in PCa. Additionally, in the same study, miR-135b,
miR-185, miR-297, miR-299-3p, miR-34a, miR-34c, miR-371-3p,
miR-421, miR-449a, miR-449b, miR-634 and miR-654-5p were
identiﬁed as direct binding partners of the 30UTR of AR (Ostlinget al., 2011). The assessment of the levels of these microRNAs,
could therefore represent a promising measurement to address the
microRNAs response upon endocrine therapy. Furthermore, miR-
26b, miR-182 and miR-200b were also previously reported to
interact with p300/CBP (Mees et al., 2010). These three miRs are
associated with ERG modulation, TMPRSS2-ERG correlation and
endocrine treatment respectively. Together these highlight the
potential of monitoring the levels of these miRs during endocrine
therapy and the relevance of targeting p300/CBP in PCa.4. microRNA interaction with GR & glucocorticoids
GCs are steroidal hormones that have been used in the treat-
ment of prostate cancer, typically in combination with docetaxel
and abiraterone acetate in the castration-resistant phase of the
disease, reviewed in (Montgomery et al., 2014). The rationale for
the administration of GCs is basically related to slow disease pro-
gression, improve pain control and reduce the side effects of
chemotherapy (Piccart et al., 1997; Attard et al., 2012). GCs can
suppress androgen synthesis through inhibition of the hypotha-
lamic/pituitary axis, which results in suppression of testicular and
adrenal androgen production (Alesci et al., 2001). However, GCs
usage remains controversial as both pro- and antitumor effects
have been documented (Montgomery et al., 2014). Additionally, GR
expression is enhanced in PCa patients who received docetaxel and
in docetaxel-resistant cell lines (Kroon et al., 2016a,b). Moreover,
GR antagonism by RU-486 and cyproterone acetate (CPA), has been
shown to revert docetaxel resistance in human PCa, opening new
possibilities for the clinical utility of the GR antagonists in the
management of patients with advanced PCa (Kroon et al., 2016a,b).
To date, only one report has highlighted the functional
connection between miRs and GR in the context of human prostate
cancer (Rane et al., 2016). Rane et al., have shown that inhibition of
the GR bymifepristone (Lin et al., 1995) results in an enhancedmiR-
99a/100 expression (Table 1) and increased radiation response in
patient-derived prostate cells (Rane et al., 2016). miR-99a and miR-
100 have been shown to be signiﬁcantly suppressed in prostate
stem-like cells (CD133þ, a2b1hi cells) compared to their differenti-
ated progeny committed basal cells (CD133, a2b1lo) (Rane et al.,
2015). CD133þ cells have been reported to be tumorigenic in vivo
after fractionation of heterogeneous bulk samples (Maitland et al.,
2011). Strikingly, the similar pattern of downregulation in micro-
RNA expression during PCa progression, documented in a remark-
able number of studies, is also observed in tumorigenic prostate
cancer stem-like cells vs. more differentiated cells (i.e. miR-99a and
miR-100 are decreased in prostate stem-like cells vs. committed
basal cells). Thus, during progression towards a more aggressive
state, there seems to be a general tendency to reduce the expres-
sion levels of tumor suppressor microRNAs.
Interestingly, TMPRSS2-ERG has been reported to be expressed
in the stem-like compartment (CD133þ, a2b1hi cells) enriched for
CD44þ cells (Birnie et al., 2008). Together, this suggest that miR-
99a/100 present in fusion-positive prostate cancer stem-like cells
might represent interesting target molecules in combination with
endocrine-therapy aimed to inhibit GR.
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The chromosomal rearrangement resulting in the formation of
the fusion gene between TMPRSS2 and the transcription factor ERG,
is detected in approximately 6% of benign prostatic hyperplasia
(BPH) and 50e60% of all PCa (Tomlins et al., 2005; Clark et al., 2007;
Visakorpi, 2012). It was reported that the frequency of the
TMPRSS2-ERG fusions in high-grade PIN lesions and localized PCa,
is about 15% and 50% respectively (Clark et al., 2008; Mosquera
et al., 2008), suggesting that this event either occurs after cancer
initiation, or alternatively predisposes to clinical progression (Shen
and Abate-Shen, 2010), althought this is not cancer restricted. It has
also been proposed that the formation of this chromosomal rear-
rangement might be controlled by androgens; AR binding in LNCaP
androgen responsive PCa cells resulted in juxtaposition between
the AR regulated promoter of TMPRSS2 and ERG (Lin et al., 2009).
Moreover, androgen signaling might recruit topoisomerase II
inducing double strand breaks even in absence of stress (Haffner
et al., 2010; Kolar et al., 2014).
Although extensive research, (reviewed in (Tomlins et al., 2009;
Visakorpi, 2012; Adamo and Ladomery, 2016; Archer et al., 2016))
has been performed in the last years, related to ERG-induced
oncogenesis in PCa, following the chromosomal rearrangements
with TMPRSS2, only few studies have functionally investigated the
reciprocal inﬂuences between microRNAs and TMPRSS2-ERG
fusion gene.
miR-221 is one of the microRNAs that was shown to be pro-
gressively downregulated in aggressive prostate cancer in hormone
naïve tumors and it has been proposed as novel prognostic
biomarker and therapeutic target in high-risk prostate cancer, be-
ing an effective predictor of clinical recurrence (Spahn et al., 2010).
Recently, miR-221 was shown to regulate prostate cancer cell
growth, invasiveness, and apoptosis via direct inhibition of SOCS3Fig. 1. Schematic representation of most important and funand IRF2, two oncogenes that negatively regulate the JAK/STAT
signaling pathway (Kneitz et al., 2014) (Fig. 1). Interestingly, Gor-
danpour et al., have shown that miR-221 is downregulated in
prostatic tumors bearing TMPRSS2-ERG fusion transcripts (Table 2)
(Gordanpour et al., 2011), providing the ﬁrst published evidence for
miRNA associations in prostate cancer that overexpress the ERG
oncogene from the TMPRSS2-ERG fusion transcript. However, it is
important to highlight that in PCa the situation seems to be more
complex, because Sun et al., (2014), have shown that miR-221
expression levels are increased in tissue derived from bone
metastasis of CRPC, which suggests a speciﬁc function of miR-221
in the development of androgen resistance. miR-221 could indeed
abolish proliferation in the SOCS3-positive and androgen inde-
pendent PC3 and Du145, but not in the SOCS3-negative and
androgen dependent LNCaP cells (Kneitz et al., 2014). Together this
supports the notion that in PCa the sensitivity against androgen
signaling depends on SOCS3 expression (Neuwirt et al., 2007) and
that miR-221 might play a pivotal role in the regulation of the
androgen-independent growth.
Remarkably, the mechanism of pathogenesis for fusione-
negative tumors compared to TMPRSS2eERG positive ones, is still
not entirely elucidated (Borno et al., 2012). Interestingly, distinct
epigenetic mechanisms distinguish TMPRSS2eERG fusion-positive
and -negative prostate cancers (Alumkal and Herman, 2012) and, as
previously discussed, DNA methylation and histone modiﬁcations
are two epigenetic mechanisms responsible for the de-regulation of
microRNAs expression (Lujambio et al., 2008). Interestingly, one of
the highly upregulated genes during prostate cancer progression is
the human homologue of the Drosophila protein Enhancer of Zeste
2 (EZH2), which belongs to the group of polycomb proteins and is
involved in silencing of homeobox genes through methylation
(Pirrotta, 1998; Hoffmann et al., 2007).
EZH2 is a target of the TMPRSS2eERG gene fusion, andctionally relevant microRNA in ERG-positive PCa cell.
Table 2
microRNAs expression modulation in TMPRSS2-ERG positive cells vs. TMPRSS2-ERG negative.
microRNAs TMPRSS2-ERG Positive (vs. Negative) Sample p-value References
miR-221 Downregulated 153 samples of radical prostatectomy p < 0.01 Gordanpour et al., 2011
miR-26a Upregulated 51 prostate cancer samples p < 0.05 Borno et al., 2012
miR-200c Downregulated 15 ERG þ vs. 14 ERG e Pca samples 0.002 Kim et al., 2014
miR-145 Downregulated 26 corresponding pairs of non-malignant prostate tissue and PCa 0.0013 Hart et al., 2013
miR-187 Downregulated 273 parafﬁn embedded PCa samples 4.94E-06 Casanova-Salas et al., 2014
miR-182 Upregulated 273 parafﬁn embedded PCa samples 1.63E-06 Casanova-Salas et al., 2014
E. Zoni et al. / Molecular and Cellular Endocrinology 462 (2018) 9e16 13TMPRSS2eERG and EZH2 cooperate in the regulation of shared
target genes, including AR (Yu et al., 2010). Aberrant DNA methyl-
ation associated with altered EZH2 expression correlates with PCa
progression and has been proposed as an early event in tumori-
genesis (Varambally et al., 2002). Interestingly, a recent report has
documented the global epigenetic alterations in fusionenegative
tumors, providing a mechanistic explanation for the formation of
these cancers (Borno et al., 2012). In this report, it has been pro-
posed that hypermethylation of miR-26a is an alternative way to
activate EZH2 in an ERG rearrangement-independent manner. miR-
26a directly targets EZH2 and it is suppressed in fusion-negative
prostate cancers (Table 2, Fig. 1) (Borno et al., 2012). This suggests
that a suppression of miR-26a caused by a hypermethylation leads
to a decreased inhibition of EZH2, leading to perturbations to the
global DNA methylation proﬁle, providing a new mechanistic
model for fusion-negative tumors (Borno et al., 2012).
Given the established notion that ERG is overexpressed in a high
proportion of the prostate carcinomas (Tomlins et al., 2005), a
relatively large part of the scientiﬁc work performed in the past
decade has focused on the molecular characteristics of these
fusion-positive tumors. The overexpression of ERG represents one
of the key factors in the switch from conﬁned to metastatic disease
(Hagglof et al., 2014) and is accompanied by loss of E-cadherin
expression, increased cell mobility and invasion (Leshem et al.,
2011). Additionally, is has been proposed that TMPRSS2-ERG pro-
motes epithelial-to-mesenchymal transition (EMT) through the
ZEB1/ZEB2 axis in PCa (Leshem et al., 2011). Interestingly, it was
recently shown that docetaxel resistant human PCa cells display
EMT features and properties of tumor-initiating cells (Puhr et al.,
2012) and experimental work revealed that these cells display
upregulation of ZEB1 and downregulation of miR-200c. Intrigu-
ingly, miR-200c has been recently identiﬁed as downstream target
of ERG and miR-200c expression in tissues from patients with ERG-
positive PCa was signiﬁcantly lower compared with ERG-negative
tumors (Table 2), supporting the notion that ERG directly re-
presses miR-200c (Kim et al., 2014). These data together indicate
that ERG might be involved in the acquisition of chemotherapy
resistance and suggest that monitoring of ERG, miR-200c and ZEB1
in PCa patient's tissues might be relevant to predict the outcome of
chemotherapy (Culig, 2014) (Fig. 1).
AnothermicroRNA relevant in the context of EMTand TMPRSS2-
ERG positive tumors is miR-30 (Kao et al., 2014). Kao et al., have
demonstrated that ERG is a direct target of miR-30 and increased
expression of miR-30 in VCaP and PC3 prostate cancer cells resulted
in reduction of EMT phenotypes and abolished migration and in-
vasion (Kao et al., 2014) (Fig. 1). miR-30 has been shown to be
signiﬁcantly downregulated in tumor vs. benign tissue and in
hormone-refractory prostate cancer (Porkka et al., 2007). Inter-
estingly, administration of selective inhibitors of Src-family tyro-
sine kinases resulted in a strong upregulation of miR-30 and
decreased ERG expression at mRNA and protein level. Given that
speciﬁc Src kinase inhibitors have been tested in Phase I, II and III
clinical trials (in combination with docetaxel (Araujo et al., 2013))
for the treatment of PCa patients, this suggests the employment ofSrc inhibitors for especially targeting ERG-positive castration-
resistant tumors. However, the role of EMT in the context of an-
drogens and androgen-regulated genes seems to be more complex:
AR splice variants appears to contribute to PCa aggressiveness and
EMT induction (Kong et al., 2015), however ADT has been shown to
generate EMT in normal and neoplastic prostate in animal models
(Sun et al., 2012).
miR-145 is a direct regulator of ERG and shown to be consis-
tently downregulated in prostate cancer (Hart et al., 2013).
Although no association between miR-145 and ERG mRNA
expression is reported, a negative correlation betweenmiR-145 and
ERG protein was demonstrated (Table 2) (Hart et al., 2013). Inter-
estingly, the documented reduction of miR-145 in PCa might sup-
port the elevated expression of multiple ERG isoforms, all detected
ERG variants display, indeed, the miR-145-responsive 30 UTR seed
sequence (Hart et al., 2013) (Fig. 1).
Finally, miR-187 also displayed a strong pattern of down-
regulation during PCa progression in a cohort of 50 PCa samples vs.
10 normal tissues (Casanova-Salas et al., 2014). These results were
validated in an independent cohort of 273 parafﬁn embedded PCa
samples and displayed an inverse correlated with TMPRSS2-ERG
expression (Table 2) (Casanova-Salas et al., 2014). Notably, in the
same study, a positive correlation between miR-182 and TMPRSS2-
ERG was detected and miR-182 was shown to be signiﬁcantly
associated with progression free survival and revealed to be a sig-
niﬁcant independent predictor of worse outcome for biochemical
progression free survival (deﬁned as PSA 0.4 ng/ml or greater
during follow-up) but not for progression free survival (deﬁned as
local, lymph nodes or distant metastasis growth) (Casanova-Salas
et al., 2014). Therefore, miR-187 and miR-182 have been proposed
as biomarkers of early diagnosis and prognosis in PCa patients
(Fig. 1). Interestingly, miR-182 has been shown to be directly
regulated by the AR and to promote prostate cancer cell prolifera-
tion, invasion and migration and inhibit apoptosis (Yao et al., 2016).
Accordingly, miR-182 expression is increased in AR-positive cell
lines, such as LNCaP, 22RV1 and C4-2, and reduced in the AR-
negative cell line DU145 (Yao et al., 2016). The association of miR-
182 with AR reinforce its positive correlation with TMPRSS2-ERG
in patient's specimens.6. microRNA and ERG based therapy
As previously discussed, ERG has been extensively shown to be
implicated in PCa initiation and progression and to be involved in
multiple processes such as EMT, invasion and metastasis. ERG
based therapy options have been recently comprehensively
reviewed by Adamo et al. (Adamo and Ladomery, 2016). In this
paragraph we highlight the connection between ERG-linked mol-
ecules, currently targeted by ERG based therapy and clinically
relevant microRNAs in PCa.
Poly(ADP-Ribose) Polymerase (PARP) is a DNA repair protein
which interacts with ERG through a DNA-independent mechanism
(Sebastian de Bono et al., 2011). Inhibition of PARP reduces the
aggressiveness of ERG-positive PCa cells. High levels of miR-182 in
E. Zoni et al. / Molecular and Cellular Endocrinology 462 (2018) 9e1614breast cancer increased the sensitivity to PARP1 inhibitors and
antagonizing of miR-182 resulted in the opposite effect (Moskwa
et al., 2011). Given the increased levels of miR-182 in AR and
TMPRSS2-ERG positive cells (Casanova-Salas et al., 2014), this re-
inforces the use of PARP1 inhibitors to target ERG-positive PCa cells.
Administration of PARP inhibitor, rucaparib, to ERG-positive and
PTEN-negative PCa cells sensitized the cells to low-dose radiation
which possibly generate DNA DSB (Chatterjee et al., 2013). Inter-
estingly, two mechanisms for PARP inhibition have been proposed:
1) inhibition of the PARP1-ETS complex, a key component for the
ERG-mediated invasion and cell growth; 2) lethality following the
accumulation of DNA DSB (Brenner et al., 2011), which supports the
described effect with radiations. Interestingly, gain-of function
screen of 1129 miRNAs in a panel of human PCa cell lines, identiﬁed
and validated miR-9 as direct regulator of AR in PCa (Ostling et al.,
2011). Moreover, in ovarian cancer, miR-9 was shown to increase
cellular sensitivity to the same PARP1 inhibitor (Sun et al., 2013). In
another report, Nowek et al. demonstrated that miR-9 directly
targets ERG (Nowek et al., 2016). Together this suggest that miR-9
might exerts a synergistic effect with ERG-targeted therapy in hu-
man PCa. miR-9 was also moderately upregulated in a panel PCa
cell lines upon administration of trichostatin A (TSA), and HDAC
inhibitor, which reduces growth of ERG-positive PCa cells and de-
ceases the expression of TMPRSS2-ERG (Table 1) (Rauhala et al.,
2010). However, in the same study, miR-193 displayed a signiﬁ-
cantly higher induction upon TSA treatment and was shown to be
downregulated in PCa samples vs. BPH, suggesting a tumor sup-
pressive role for this microRNA (Table 1) (Rauhala et al., 2010).
Another microRNA interesting for its pattern of expression during
disease progression is miR-1296. This microRNA is downregulated
in PCa tissues compared to BPH and directly targets the mini-
chromosome maintenance gene 2 (MCM2) (Majid et al., 2010).
MCM2 is involved in DNA replication, is upregulated in PCa and
correlates with poor survival (Meng et al., 2001; Majid et al., 2010).
Interestingly, TSA treatment in PCa cell lines PC3 and LNCaP cell
resulted in decreased MCM2 protein expression (Majid et al., 2010),
suggesting that miR-1296 might represent another molecule with
synergistic properties to reduce growth of ERG-positive PCa cells.
Finally another strategy for ERG-based therapy is its direct tar-
geting with molecules promoting degradation. USP9X is a
ubiquitin-speciﬁc peptidase which stabilizes ERG and knockdown
of USPX9 resulted in increased ERG degradation, following ubiq-
uitination (Adamo and Ladomery, 2016). Inhibition of USP9X with
direct inhibitor WP1130, resulted in ERG degradation and inhibited
growth of ERG-positive tumors in vivo (Wang et al., 2014). Inter-
estingly, miR-26b has been shown to directly target USP9X (Shen
et al., 2014) and is markedly downregulated in PCa tissues (Kato
et al., 2016). This suggests that miR-26b replacement therapy
might inhibit USP9XP, leading to ERG degradation and inhibition of
ERG-positive PCa. Given the positive outcome of preclinical studies
which employed non-toxic liposomal nanovectors to selectively
knockdown TMPRSS2-ERG fusion (Shao et al., 2012), this opens
new scenarios for microRNA replacement therapies and for the
delivery in situ of miRNA mimics capable of interfering with ERG
signaling, in combination with ERG-targeted therapy.
7. Conclusion and perspectives
In this review, we discussed and summarized the interactions
between microRNAs and endocrine-related aspects of prostate
cancer. We discussed multiple aspects of androgen- and
glucocorticoid-targeted therapy and the inﬂuences of these treat-
ments on the modulation of microRNA expression. We speciﬁcally
highlighted the different approaches to investigate the connections
between microRNAs and the androgen-regulated gene TMPRSS2-ERG and also discussed novel insights into the effect of GR target-
ing in advanced prostate cancer and microRNAs.
The diagnostic and prognostic value of microRNAs is nowadays
clear. Non-coding RNAs can be employed as biomarkers and pre-
dictors of therapy response. However, the applicability of miRs as
therapeutic agents in oncology is still in its developmental phase,
mainly due to therapeutic delivery challenges. The intrinsic a-
speciﬁcity that microRNAs present is one of the biggest challenge in
the achievement of anti-tumor response with acceptable side ef-
fects. Additionally, the microenvironment and tissue dependent
“dual” function of microRNAs as tumor suppressors or oncogenes is
one of the main challenges for a therapeutic approach.
We believe that miRNA targeted therapy will be attempt, once
that a selective therapeutic delivery system will be developed to
speciﬁcally target cancerous cells. Meanwhile, the employment of
microRNAs as predictors of therapeutic outcome is one of the
strategies for better patient stratiﬁcation and treatment response in
the perspective of a personalized medicine era.
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